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The death rate due to cancer has not improved over the past five decades (3).
Anthracyclines, such as doxorubicin, are some of the most effective anti-cancer
chemotherapy agents used to treat several cancers. However, the use of
anthracyclines is limited due to the chronic and potentially lethal cardiotoxicity
associated with these drugs. The mechanism involves the two-electron
reduction of the C-13 carbonyl group of the anthracyclines by carbonyl
reductase (CBR). The resulting alcohol metabolites of anthracyclines
(doxorubicinol and daunorubicinol) not only contribute to cardiotoxicity, but also
possess diminished cytotoxicity against cancer cells (1). Therapeutic
approaches to regulate CBR expression and/or activity may lead to increased
efficacy of anthracyclines for cancer therapy and decrease the cardiotoxicity
associated with the use of these drugs.
Recent evidence links aryl hydrocarbon receptor activation to the induction of
CBR (2). The AhR is a soluble, ligand-activated transcription factor that
modulates expression of genes involved in xenobiotic metabolism, apoptosis,
and cell proliferation and differentiation (4). The goal of this study was to use an
AhR agonist and antagonist to determine how AhR activation regulates CBR
protein expression in a rat hepatoma cell line (5L cells). We also tested the
hypothesis that doxorubicin induces CBR expression through a pathway that
involves AhR activation. To this end, 5L cells were treated with the
drugs/chemicals shown in Table 1, and cell extracts were analyzed by western
blot to detect CBR, as well as Cyp1a1, which is an AhR-regulated gene whose
expression is indicative of AhR activation.
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Figure 1. Proposed relationship between AhR activation 
and CBR induction.
AhR = Aryl Hydrocarbon Receptor 
ARNT = Aryl Hydrocarbon Receptor Nuclear Translocator 
CBR = Carbonyl Reductase 
TCDD = 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
XRE = Xenobiotic Response Element 
1. Future studies will consist of dose response and time course studies to determine the
effects of DOX on CBR expression levels and AhR activation.
2. We will also perform DOX cytotoxicity studies for killing in presence/absence of AhR
(using AhR-positive and AhR-defective cells) to see whether inhibiting the activity of
AhR will impact DOX cytotoxicity.
3. We will also perform an Alamar Blue assay with a combination of DOX and RES to
determine the IC50 value of DOX in the presence of RES. This will reveal whether RES
can lower the IC50 value of DOX and enhance DOX cytotoxic activity through the
inhibition of cellular metabolic activity.
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• Our data confirm that DOX induces CBR protein expression, which agrees with previous
studies. However, we don’t know the exact mechanism by which this is taking place. Our
proposed mechanism postulates that induction of CBR by DOX occurs through the AhR
pathway. If DOX induces CBR through the AhR pathway then the inhibition of AhR will
provide a means for controlling CBR protein expression during anthracycline treatment.
•TCDD is known for inducing Cyp1a1 protein expression via the AhR pathway, which is
shown in our data (Fig. 3). However, we observed that when rat hepatoma 5L cells were
cotreated with TCDD + TRI, a decrease in Cyp1a1 protein expression was observed. This
could mean that TRI is an inhibitor of AhR signaling. TRI is a documented CBR inhibitor.
•Treatment of TCDD in combination with DOX or RES showed higher levels of CBR
activity than in cells treated with DOX or RES alone. Even though RES is known to inhibit
the AhR pathway, its inhibition may be masked by the potent induction of CBR activity by
TCDD.
•Cell viability measurements using an Alamar Blue assay revealed that DOX has an IC50
value of 200nM (Fig.5), which indicates that 200nM is the amount of DOX required to
inhibit half of the cellular metabolic activity.
Figure 4. Doxorubicin treatment diminishes viability of 5L cells.
Rat hepatoma 5L cells were grown to 80% confluency . Cells were treated with DOX for 24 hours .  
Alamar Blue was added to measured  the percent viability of the cells.
Figure 2. Consequences of chemical treatment on protein expression.
Western blot showing the induction of (A) CBR3 and (B) Cyp1a1 protein expression in rat hepatoma 
5L cells treated for 24 hr with the indicated chemicals.
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RESULTS
Drug or chemical Abbreviation Final 
concentration 
Function 
2,3,7,8-
Tetrachorodibenzo-p-
dioxin 
TCDD 10 nm AhR agonist 
Resveratrol RES 25 mm AhR antagonist 
Doxorubicin DOX 5 mm Induces CBR
Triclosan TRI 25 mm Inhibits CBR
TABLE 1: Description of drugs/chemicals used in this study.
Rat hepatoma 5L cells were grown to 70% confluency. Cells were washed with PBS and treated with the chemicals
listed above, or combinations of these chemicals, for 24 hours. Cells were then washed and collected using RIPA lysis
buffer that contained protease inhibitors. Cell extracts were quantified using a Lowry protein assay and resuspended in
SDS loading buffer. Cell extracts were run on 10% SDS polyacrylamide gels at 50 ug protein per lane. Gels were
transferred to PVDF membranes, blocked with Superblock (Fisher Scientific), and incubated with antibodies against
CBR or Cyp1a1, followed by HRP-conjugated secondary antibodies. Protein bands were visualized with
chemiluminescence.
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Figure 3. Consequences of chemical treatment on CBR enzyme activity.
Enzymatic study to measure carbonyl reductase activity in cell lysates.
PROPOSED MECHANISM
